SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Natera Says Signatera ctDNA Dynamics Predicted EFS in MIBC Trial

Natera said phase III VOLGA trial data presented at an ESMO Presidential Symposium showed 24-month event-free survival of 91% for persistently negative patients, 81% for patients whose ctDNA cleared before surgery and 55% for persistently positive patients.

NTRA

Related stories